Pharmacy Lien Trends 2026: What PI Attorneys Need to Know

James Wong — Founder & Pharmacist, LienScripts | February 20, 2026 | 9 min read

Eight major trends are reshaping pharmacy liens in personal injury practice in 2026, from PBM reform legislation and rising specialty medication costs to AI-driven documentation and increased insurer scrutiny. PI attorneys who understand these shifts can protect case value and improve client outcomes through the LienScripts platform.

Pharmacy lien services in personal injury practice are undergoing significant transformation in 2026, driven by federal PBM reform legislation, rising specialty drug costs, AI-powered documentation tools, and evolving insurer defense tactics. PI attorneys who track these trends position themselves to maximize case value and maintain uninterrupted client medication access. The eight trends covered in this article represent the most consequential changes affecting pharmacy lien strategy for personal injury firms this year.

• PBM reform legislation at federal and state levels is increasing pharmacy reimbursement transparency, though pharmacy liens through LienScripts bypass PBMs entirely
• Specialty medication costs continue rising, increasing lien values in cases involving biologics, CGRP inhibitors, and other high-cost therapies
• AI and automation are transforming pharmacy lien documentation, with LienScripts generating MERIT (Medication Evaluation & Rationale for Injury Treatment) reports with technology-enhanced accuracy
• Defense counsel and insurers are deploying more sophisticated challenges to pharmacy lien amounts
• Telehealth prescribing expansion and multi-state pharmacy networks are broadening medication access for PI plaintiffs

Trend 1: PBM Reform Legislation Advances

The Federal Trade Commission's 2024 report on pharmacy benefit manager practices triggered a wave of reform legislation that is taking effect across multiple states in 2026. According to the National Academy for State Health Policy, over 30 states have enacted or are considering PBM transparency laws requiring disclosure of spread pricing, rebate retention, and formulary placement criteria.

At the federal level, the bipartisan Pharmacy Benefit Manager Reform Act continues advancing through committee, targeting the three largest PBMs that control approximately 80% of prescription drug adjudication. Key provisions include prohibiting spread pricing in Medicaid managed care, requiring pass-through of manufacturer rebates, and mandating formulary transparency.

For PI attorneys, PBM reform matters because PBM practices determine which medications insurers cover and at what cost. However, pharmacy liens through LienScripts operate entirely outside the PBM system. Medications are dispensed based on clinical need without insurance adjudication, formulary restrictions, or step therapy requirements. PBM reform may eventually improve the insurance landscape, but attorneys who connect clients with the LienScripts platform insulate those clients from PBM-related barriers immediately.

[!KEY] PBM reform is progressing but remains incomplete. Pharmacy liens through LienScripts bypass the PBM system entirely, providing immediate medication access regardless of reform timelines.

Trend 2: Rising Specialty Medication Costs Drive Higher Lien Values

Specialty medication spending in the United States grew 12.4% in 2025, according to IQVIA's Drug Expenditure Report. CGRP inhibitors for post-traumatic migraines (Aimovig, Ajovy, Emgality), biologics for complex pain conditions, and newer psychiatric medications for treatment-resistant PTSD now appear regularly in personal injury medication regimens. These medications carry significantly higher per-unit costs than traditional generics, which increases the total lien value when cases involve specialty therapies.

According to James Wong, PharmD, founder of LienScripts, "The trend toward specialty medications in personal injury is driven by clinical need, not cost. When a patient with post-traumatic migraines fails conventional prophylaxis, CGRP inhibitors are the appropriate next step. The lien ensures that clinical decisions are not constrained by cost, and the MERIT report documents the clinical rationale for each medication choice."

PI attorneys should expect higher lien amounts in cases involving specialty medications and should understand the clinical justification for each therapy. The LienScripts MERIT (Medication Evaluation & Rationale for Injury Treatment) report documents the treatment progression that led to specialty medication use, which supports the medical necessity argument in demand packages and at mediation.

[!KEY] Specialty medication costs are rising, but clinical documentation through MERIT reports provides the medical necessity foundation that supports higher lien values during settlement negotiations.

Trend 3: AI and Automation in Pharmacy Lien Documentation

Artificial intelligence is transforming how pharmacy lien documentation is created, reviewed, and presented. AI-powered systems now automate medication timeline generation, identify adherence patterns, detect potential drug interactions, and flag treatment gaps that human reviewers might overlook. The LienScripts platform incorporates technology-driven documentation processes to produce more comprehensive and accurate MERIT reports.

Key AI applications in pharmacy lien documentation include:

Automated drug utilization review. AI systems analyze dispensing patterns against clinical guidelines to identify whether the medication regimen is consistent with the documented injuries and treatment standards.

Treatment gap detection. Machine learning algorithms identify gaps between expected refill dates and actual fill dates, documenting periods where the patient may have gone without medication.

Pattern recognition. AI identifies dose escalation patterns, medication switches, and multi-drug coordination that support the narrative of treatment complexity and injury severity.

Consistency verification. Automated checks ensure that medication records, prescriber notes, and clinical documentation align, reducing errors that defense counsel could exploit.

[!KEY] AI enhances documentation quality without replacing clinical judgment. Every MERIT report from LienScripts is reviewed and signed by a licensed pharmacist, with AI handling data compilation and pattern identification.

Trend 4: Increased Insurer Scrutiny of Pharmacy Liens

Insurance carriers and defense counsel are developing more sophisticated strategies for challenging pharmacy lien amounts. Common defense tactics in 2026 include:

AWP vs. acquisition cost arguments. Defense experts argue that lien amounts based on Average Wholesale Price (AWP) exceed the pharmacy's actual acquisition cost, seeking to reduce lien payouts. The American Pharmacists Association has published position papers explaining why AWP-based pricing reflects the full cost of dispensing services, clinical review, and documentation.

Medical necessity challenges. Insurers increasingly retain pharmacist experts to review medication regimens and challenge the necessity of specific medications, particularly specialty drugs and branded products.

Temporal causation disputes. Defense strategies now more frequently challenge whether medications prescribed months after the accident are causally related to the injury.

PI attorneys should prepare for these challenges by ensuring robust clinical documentation. The LienScripts MERIT report addresses each of these defense angles by documenting medication necessity, clinical rationale for prescribing decisions, and the temporal relationship between injury and treatment.

[!KEY] Stronger defense tactics demand stronger documentation. MERIT reports from LienScripts provide the pharmacist-signed, evidence-based documentation that withstands insurer scrutiny.

Trend 5: Telehealth Prescribing Expands Access

The permanent extension of telehealth prescribing flexibilities adopted during the pandemic is expanding medication access for PI plaintiffs in 2026. Patients who cannot travel to in-person appointments due to injury limitations can now receive prescriptions via telehealth consultations, which the LienScripts pharmacy network can fill under the lien. This is particularly significant for plaintiffs in rural areas or those with mobility limitations.

Telehealth prescribing also accelerates the time from injury to treatment initiation. Attorneys who connect clients with LienScripts early in the case can facilitate faster medication access through combined telehealth consultation and pharmacy lien dispensing.

Trend 6: Multi-State Practice Growth

National pharmacy networks are enabling multi-state personal injury practice to scale more effectively. The LienScripts platform operates across all 50 states, which means attorneys handling cases in multiple jurisdictions can use a single pharmacy lien partner rather than coordinating with state-specific providers. This trend toward national platforms reduces administrative burden and ensures consistent documentation quality regardless of jurisdiction.

Trend 7: MERIT Reports Becoming Standard in Demand Packages

The MERIT (Medication Evaluation & Rationale for Injury Treatment) report is increasingly recognized by insurance adjusters and mediators as a standard component of well-prepared demand packages. Attorneys who include MERIT documentation receive fewer challenges to medication-related damages because the report preemptively addresses medical necessity, treatment progression, and clinical rationale.

LienScripts generates a MERIT report for every case, providing pharmacist-signed documentation that serves as both a medication summary and an expert clinical narrative. As more firms adopt this documentation standard, attorneys who omit pharmacy-level documentation risk appearing less prepared than opposing counsel.

Trend 8: Platform Consolidation in Lien Services

The pharmacy lien services market is consolidating around technology-enabled platforms that offer end-to-end case management, automated documentation, and national pharmacy networks. Smaller, manual-process lien providers are being displaced by platforms like LienScripts that combine pharmacy expertise with purpose-built technology. For attorneys, this consolidation means fewer but more capable partners, with better documentation, faster turnaround, and more consistent service quality.

What These Trends Mean for PI Attorneys in 2026

The convergence of these eight trends creates both opportunity and risk for personal injury firms. Attorneys who adapt will benefit from higher case values through better documentation, broader medication access through national platforms, and stronger defense against insurer challenges through AI-enhanced MERIT reports. Attorneys who do not adapt risk losing case value to underdocumented medication claims and falling behind firms that leverage modern pharmacy lien partnerships.

The LienScripts platform addresses each of these trends through its combination of national pharmacy network access, AI-enhanced documentation, pharmacist-signed MERIT reports, and technology-driven case management. PI attorneys who establish pharmacy lien partnerships now position their practices for the evolving landscape of 2026 and beyond.